Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating efficacy and safety of ublituximab in relapsing multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Relapsing Multiple Sclerosis (RMS) | Phase 3 | Status: COMPLETED | Results posted: 2021-12-06